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Popianna Tsiortou, Harry Alexopoulos and Marinos C. Dalakas

Abstract: Antibodies against glutamic acid decarboxylase (GAD), originally linked to stiff
person syndrome (SPS), now denote the “GAD antibody-spectrum disorders” (GAD-SD) that
also include autoimmune epilepsy, limbic encephalitis, cerebellar ataxia and nystagmus with
overlapping symptomatology highlighting autoimmune neuronal excitability disorders. The
reasons for the clinical heterogeneity among GAD-antibody associated syndromes remain
still unsettled, implicating variable susceptibility of GABAergic neurons to anti-GAD or other
still unidentified autoantibodies. Although anti-GAD antibody titers do not correlate with
clinical severity, very high serum titers, often associated with intrathecal synthesis of antiGAD-specific IgG, point to in-situ effects of GAD or related autoantibodies within the central
nervous system. It remains, however, uncertain what drives these antibodies, why they persist
and whether they are disease markers or have pathogenic potential. The review, focused on
these concerns, describes the widened clinical manifestations and overlapping features of
all GAD-SD; addresses the importance of GAD antibody titers and potential significance of
GAD epitopes; summarizes the biologic basis of autoimmune hyperexcitability; highlights the
electrophysiological basis of reciprocal inhibition in muscle stiffness; and provides practical
guidelines on symptomatic therapies with gamma-aminobutyric acid-enhancing drugs or
various immunotherapies.
Keywords: autoantibodies, cerebellar ataxia, encephalitis, GAD autoimmunity,
hyperexcitability, stiff person syndrome
Received: 23 February 2021; revised manuscript accepted: 27 February 2021.

Introduction
GAD (glutamic acid decarboxylase) is a pyridoxal
5'-phosphate-dependent enzyme, widely expressed
within the central nervous system and pancreatic
β-cells, that catalyzes the conversion of the excitatory neurotransmitter l-glutamate to the inhibitory neurotransmitter gamma-aminobutyric acid
(GABA).1 Autoantibodies against GAD were first
detected in 1988 in a patient with stiff person syndrome (SPS), epilepsy and type-1 diabetes mellitus (DM-1), pointing out to an immunological
connection between SPS, DM-1 and epilepsy
and highlighting since then that disruption of
GABAergic neurotransmission results in neuronal
excitability.2 Over the ensuing years, anti-GAD
antibodies have been also connected with other

autoimmune neurological diseases associated with
neuronal excitability that now comprise the
“GAD antibody-spectrum disorders” (GAD-SDs)
and include SPS, autoimmune epilepsy, cerebellar ataxia, limbic encephalitis, myoclous and
nystagmus.3
As the clinical spectrum of GAD-SD in now widened and their overlapping symptomatology more
clearly recognized, a number of puzzling clinical
connections, diagnostic dilemmas and pathogenetic mechanisms have emerged. New information about GAD epitopes and the importance of
GAD titers has further strengthened their specificity in defining GAD-SD. While low GAD antibody titers directed at different epitopes are seen
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in 80% of patients with DM-1,4 and up to 30% of
patients with GAD-SD also have DM-1, only
patients with typical GAD-SD neurological syndromes exhibit very high titers. The paper aims to
describe the evolved clinical manifestations of
GAD-SD; discuss why antibody titers matter in
diagnosis and immunopathogenesis; highlight
how GABAergic neurotransmission results in
such diverse clinical phenomena with reciprocal
inhibition and muscle stiffness; and summarize
the best therapeutic options to treat autoimmune
neuronal excitability. Considering that SPS is not
as rare as has been thought, but still misdiagnosed, based on the large number of patients seen
in our clinic, the review is hoped to increase the
awareness of these syndromes for practicing neurologists and facilitate early diagnosis and prompt
therapy initiation.
Clinical manifestations
SPS
SPS, first described by Moersch and Woltman in
1956,5 is the commonest and most characteristic
clinical subtype of GAD-SD. Although its precise
frequency is unclear, based on the large number of
patients referred to us in the last 30 years and having the opportunity to screen, examine, treat and
follow many such patients in-person, rather than
from chart reviews and retrospective data collection, we believe it is a fascinating disorder, more
common than previously thought, but still underrecognized or misdiagnosed. SPS is twice as common in women than men, frequently represented
among African-American women, with an average
age of onset at around 30–35 years.6,7 Patients typically present with muscle spasms and stiffness,
concurrently in the thoracolumbar paraspinal and
abdominal muscles, resulting in difficulties turning and bending, and progressive muscle rigidity
with hyperreflexia and spasms, mainly in the truncal and proximal leg muscles.8 Severe truncal stiffness resembles a “statue” or a “freezing”-like
appearance and patients often describe that they
walk like a “tin-man”. They often have an accompanying severe anxiety, often misdiagnosed as a
primary anxiety disorder, and task-specific phobias9 that include fear of walking and falling.
Symptoms of muscle spasms and stiffness can be
precipitated by unexpected stimuli, including
sounds, like a phone ringing or a siren, sudden
touches or emotional upset. In some cases these
events can cause severe and continuous painful
2

spasms, along with stiffness in the thoracic muscles with breathing difficulties, tachycardia and
hyperhidrosis, a condition we have labeled “status
spasticus”, requiring emergency admission for
intravenous diazepam.10 Electrophysiological
studies have revealed continuous activity of motor
unit firing at rest, confirming that stiffness is
caused by co-contractions of agonist and antagonist muscles.11–13 Normal physiology is governed
by reciprocal inhibition, which means that when
one muscle (i.e. biceps) contracts, its antagonist
(i.e. triceps) is automatically inhibited. Stimulated
gamma neurons of the agonist muscle send information to the spindles to contract, while the
antagonist’s gamma neurons do not discharge due
to inhibition of GABA interneurons (Figure 1). In
pathologic situations of impaired GABAergic neurotransmission, as occurs in SPS due to reduced
GABA from the cerebral motor pathways, the
gamma motor neurons discharge continuously
because inhibitory signals are inhibited, resulting
in bursting overstimulation of the muscle spindles
expressed as simultaneous hypercontraction of
both agonist and antagonist muscles (Figure 1).
This is clinically manifested with muscle rigidity
and stiffness and electrophysiologically as continuous motor unit activity in agonist and antagonist
muscles. Up to 80% of SPS patients have autoantibodies against GAD, the rate-limiting enzyme
for GABA synthesis.14 These antibodies may
interfere in vitro with GABA production and
in vivo with the entire GABAergic system,15,16
explaining the unbalanced neurotransmission and
the ensuing enhanced hyperexcitability expressed
as spasms and stiffness. Since GAD is also
expressed in pancreatic cells and patients with
DM-1 have low-titer anti-GAD antibodies, as discussed below, up to 35% of SPS patients may also
have DM-1 along with and other autoimmune
diseases, such as vitiligo, pernicious anemia, celiac
disease or thyroiditis.4,17,18
The diagnostic criteria for SPS, as revised in 2009,17
include: (1) stiffness of the axial muscles, particularly the abdominal and thoraco-lumbar paraspinals, leading to hyperlordosis; (2) superimposed
painful spasms triggered by unexpected tactile or
auditory stimuli; (3) severe anxiety with task-specific phobias especially in anticipation of physically
challenging tasks; (4) electromyographic evidence
of continuous motor unit activity of agonist and
antagonist muscles; (5) absence of other neurological findings that may suggest an alternative diagnosis; and (6) highly positive GAD-antibody titers by
journals.sagepub.com/home/tan
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Figure 1. Reciprocal inhibition and stiffness generation in stiff person syndrome patients.

(a) Normal function: when one muscle is contracted, its antagonist is automatically inhibited. Afferent Ia sensory neuron
fires, bringing information to the spinal cord, and stimulates the gamma neurons. Then, the gamma-motor neurons of the
agonist muscle send signals to the spindle to contract [1], while the gamma motor neurons of the antagonist muscle do not
discharge (X) due to inhibition of GABA interneuron [3]. As a result, the alpha-motor neuron of antagonist stretches (relaxes)
the muscle (2) (interneuron: releases inhibitory mediators).
(b) Pathology: if the motor neuron is continuously firing signals, while there is no inhibition of the GABA interneuron to the
antagonist muscle, the whole muscle will continuously be stimulated and will become hypertonic (spastic), without the
ability to stretch (relax), due to concurrent contraction of the agonist and the antagonist muscles, as happens in stiff person
syndrome that presents with stiffness and hyperexcitability.

immunocytochemistry, Western blot, enzyme
linked immunosorbent assay (ELISA) or radioimmunoassay. Although these criteria best describe
“classic or typical SPS”, some patients with positive
anti-GAD antibodies may not exhibit all the aforementioned symptomatology.
In our longitudinal study of 57 anti-GAD-positive
SPS patients, which represents the largest clinical
series of personally examined patients every
6 months for a two-year period to assess disease
progression, the most common initial symptom
was the insidious onset of proximal leg stiffness
followed by rigidity in the lumbosacral paraspinals, thoracic and abdominal muscles. Axial muscle stiffness (truncal and proximal legs), lumbar
hyperlordosis and impaired gait were first signs in
68% of these patients with 28% of them also having various degrees of facial muscle stiffness.19
About 15% of the patients with typical SPS symptomatology also had ataxia, dysarthria and
journals.sagepub.com/home/tan

dysphagia, overlapping with the cerebellar variant,
as described below, an important distinction
because these patient subsets do not fully respond
to immunotherapies.20 Exaggerated reaction to
various external stimuli and “startle response”
were present in all patients except two. Marked
anxiety related to unprotected falls or in anticipation of physically challenging situations was seen
in 52 of 57 patients; 21 patients experienced
chronic anxiety combined with intermittently
depressed mood. Simple phobias, such as fear of
walking in open and crowded places, crossing a
street or taking escalators, were reported by more
than 10% of patients with several also having taskrelated phobias, such as fear of public speaking.
Most patients had been misdiagnosed with
conversion or functional disorder because their

falls were attributed to avoidant behavior and
heightened mental anticipation. Other common
misdiagnoses were myelopathies, dystonias or
Parkinsonism. Many patients reported muscle
3
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Figure 2. Autoantigenic targets associated with the Central Nervous System inhibitory synapses in patients
with stiff person syndrome.

The pre-synaptic antigens are GAD (1), the enzyme that synthesizes GABA, the main inhibitory neurotransmitter, and
amphiphysin (2), a synaptic vesicle protein responsible for endocytosis of plasma membranes following GABA release.
Post-synaptically, the main targets are GABA-A Receptor Associated Protein (GABARAP) (3), gephyrin (4), a tubulin-binding
protein needed for clustering both GABA-A (5) and glycine receptors (6). The most common antigen in stiff person syndrome
is GAD followed by glycine receptor (vesicular inhibitory amino acid transporter; VIAAT). Modified from Dalakas.118
GABA, gamma-aminobutyric acid; GAD, glutamic acid decarboxylase.

pain along with painful spasms and some had
been on narcotics.
Although some patients may manifest concurrent
neuropsychiatric symptomatology that when
prominent necessitates the need for psychiatric
advice, others have been labeled as having a functional disorder. Formal neuropsychiatric testing in 10
consecutive patients seen at the (National Institutes
of Health NIH) did not meet Diagnostic and
Statistical Manual for Mental Disorders IV criteria
for phobic disorder.9 It was felt by our mental health
colleagues at the National Institutes of Mental
Health (NIMH) that the patients perceived their
fears and anxiety as realistic, arising from
4

the possibility of falls caused by SPS.10 This still,
however, remains a puzzling interpretation since
we do not see such phenomena in other neurological disorders that present with weakness and falls.
Apart from the antibodies against GAD, other antibodies may also be positive in patients with SPS
and hyperexcitability syndromes (Figure 2). We
had found antibodies against GABAA receptorassociated protein in about 70% of the patients,19
but these findings have not been replicated. Another
autoantibody found in 10–15% of SPS patients is
against glycine-a1 receptor (GlyR), a key inhibitory
neurotransmitter. Anti-GlyRa1 antibodies, first
described in progressive encephalomyelitis with
journals.sagepub.com/home/tan
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rigidity and myoclonus (PERM),21,22 as discussed
below, may be pathogenic as they recognize extracellular epitopes of the receptor expressed in the
spinal cord, brainstem and cerebellum. Low-titer
autoantibodies against GABAA receptor are also
found in 10% of patients with SPS, cerebellar
ataxia, epilepsy or encephalitis.3 In about 5% of
patients, SPS can be paraneoplastic, associated
with antibodies against amphiphysin23,24 and in a
single case against gephyrin.25 Apart from GlyR all
targeted antigens are predominantly cytoplasmic
and it remains to be determined whether they can
transiently exhibit an extracellular domain during
neurotransmission and exocytosis that may account
for pathogenicity.26
Cerebellar ataxia
Anti-GAD antibody-associated cerebellar ataxia
is the second most frequently encountered GADrelated neurological disorder within the GADSDs. It affects more women than men, often with
comorbid DM1 or polyendocrine autoimmunity.27–31 These patients exhibit gait and limb
ataxia, nystagmus, severe dysarthria, dysphagia
and oculomotor dysfunction, most often overlapping with the typical SPS symptomatology that
worsens the overall clinical picture.32 CSF analysis may show oligoclonal bands, without protein
elevation, and intrathecal anti-GAD antibody
synthesis.20,28 Although in an old prospective
study of 320 patients with sporadic cerebellar
ataxia only six (2%) had GAD antibodies,33 the
frequency is probably higher today.
Whether the antibodies play a role in the pathogenesis of cerebellar ataxias is unclear.34 Recent studies
showed that a monoclonal GAD65Ab interferes with
GABAergic neurotransmission in brain slice preparations and in vivo elicits in animals neurophysiological
and behavioral effects mimicking cerebellar ataxias.35
Intracerebellar administration of IgGs from CSF of
patients with GAD-associated cerebellar ataxia
impairs cerebellar modulation of motor control and
contributes to lack of coordination.36–40 The antiGAD antibodies seem to act on nerve terminals of
GABAergic interneurons depressing the release of
GABA, resulting in hyperexcitability and eventually
loss of Purkinje cells with diffuse proliferation of
Bergmann glia.41,42 Furthermore, a human monoclonal GAD65Ab elicits some pathogenic effects resembling those induced by cerebrospinal fluid (CSF)
IgGs.35,39 These patients may have overlapping clinical manifestations with epilepsy and SPS.43 The
journals.sagepub.com/home/tan

magnetic resonance imaging (MRI) of cerebellar
ataxia patients is normal with rare instances of mild
cerebellar atrophy,28 implying a functional blockade
rather than a destructive process, hence the need to
pursue immunotherapies.17,44
Autoimmune epilepsy
GAD antibodies were first associated with drug
refractory temporal lobe epilepsy in 1998.45 It is
considered the third most common GAD65 neurological autoimmunity, and probably one of the
most common causes of autoimmune epilepsy.46 In
early retrospective studies of 200 cases, GADantibodies were most frequent in patients with
chronic pharmaco-resistant epilepsy, who often
presented with temporal lobe epilepsy, epilepsia
partialis continua or refractory convulsive and nonconvulsive status epilepticus,47–49 without inflammatory markers in the CSF or MRI but higher
frequency of autoimmune comorbidities.48,49
In other retrospective series, anti-GAD antibodies
were detected in 22% of patients with various epilepsies and concurrent autoimmune associations.50
In a cohort of 233 patients with all types of epilepsy, the percentage of GAD-Abs was only
2.3%,51 but when dissecting out the patients with
focal epilepsy, GAD-Abs were present in 16% of
all cases,52 while among patients with temporal
lobe epilepsy the percentage was up to 21.7%.53 In
a series of 1510 epileptic patients, three had musicogenic reflex seizures (MRSs) with two of them
having GAD-associated epilepsy.54 MRSs have
also been reported in a patient with SPS comorbidity.55 Although this clinical manifestation is
extremely rare, MRS may be a distinctive type of
epilepsy highlighted by anti-GAD antibodies,
necessitating the need to test for GAD antibodies
in all suspected MRS cases, even with normal
structural MRI.54 Among 13 children with epilepsy and mean age of 6 years (range 1–13 years),
seven with suspected autoimmune epilepsy were
positive for neuronal surface antibodies (N-MethylD-Aspartate Receptors in 3, Voltage Gated
Potassium Channel-complex in one and GAD in
another). Immunotherapy in nine neuronal surface
antibody-positive cases was reported effective.56
Cytotoxic T lymphocytes have been found in histological preparations of temporomesial tissue from
patients with pharmaco-resistant epilepsy associated with GAD antibodies who underwent temporal lobectomy.57 These T cells may release perforin
5
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and granzyme, leading to necrosis, apoptosis or
electrical silencing of the respective neurons.58 It
has been suggested on these findings that epilepsy
may be caused by potentially neurotoxic CD8+
cells against GABAergic interneurons.59
The anti-GAD antibodies, by inhibiting GABAergic
pathways, may result in hyperexcitability, which
can explain epileptogenesis. The intrathecal synthesis of GAD antibodies has been proposed to
suggest degeneration of GABAergic neurons and
release of cytoplasmic proteins into the CSF, leading to an antibody-mediated immune response.2
Such a humoral response may potentially inhibit
the function of GAD, decrease the conversion of
glutamate to GABA and eventually result in
excessive excitatory neurotransmission that lowers the seizure threshold, contributing to manifestation of drug-resistant epilepsy.60 At least 5% of
SPS patients have seizures,61,62 although in our
experience the epilepsy in SPS is not refractory
but rather easily controlled. On the other hand,
only a small number of patients with GADassociated epilepsy seem to respond to routine
immunomodulating therapies, requiring more
aggressive immunosuppressants.59
Limbic encephalitis
Autoimmune limbic encephalitis with anti-GAD
antibodies clinically presents like the classic autoimmune or paraneoplastic limbic encephalitis,63
with impaired working memory, psychiatric
symptoms, seizures or altered level of consciousness.64 In some patients there are oligoclonal
bands in the CSF and intrathecal synthesis of
GAD-Abs65 but the causative role of GAD antibodies remains unclear.
PERM
PERM, described the same year as SPS by
Campbell and Garland, was considered as an SPSspectrum disorder.66 PERM is now a distinct syndrome characterized by muscle stiffness, spasms,
myoclonus and brainstem dysfunction with oculomotor abnormalities, dysphagia, gait ataxia prominent autonomic involvement and depressed level of
consciousness.67 It seems equally present in men
and women although in our small series all patients
were men. The hallmark of this disorder is the presence of anti-GlyR antibodies. As mentioned earlier,
up to 15% of SPS patients with anti-GAD antibodies also harbor low titers of anti-GlyR-Abs.68–70
6

An underlying tumor, especially thymoma or lymphoma, can be detected in about 20% of PERM
patients.71 Another autoantibody detected in four
patients with PERM is anti-DPPX,62 characterized
by diverse symptomatology including prominent
gastrointestinal manifestations, seizures, encephalopathy, sleep disturbance and dysautonomia.
Limited histological data on PERM has demonstrated inflammatory and microglial changes and
cell loss in the pons, medulla, cerebellum, spinal
cord and autonomic ganglia.8 Some PERM patients
had increased T2 fluid-attenuated inversion recovery signal of spinal cord and brainstem on MRI.67
In our small series, PERM is highly responsive to
immunotherapies, especially if started early.
Nystagmus and abnormal eye movements
Isolated oculomotor dysfunction, characterized
mainly by downbeat nystagmus and saccadic
intrusions/oscillations but rarely opthalmoparesis,
can be also associated with anti-GAD antibodies.
In our experience, oculomotor dysfunction is not
unusual among all GAD-positive patients with
SPS, especially those with cerebellar ataxia.72–75
The most common isolated GAD-positive oculomotor dysfunction is persistent horizontal or
downbeat nystagmus, presumably related to excitability of vestibular nuclei driving the motor neurons of the ocular muscles, resulting in upward
slow phase with quick compensatory downward
phase or horizontal saccades.73,76,77 Within the
GAD-SDs, opsoclonus and myoclonus have been
also observed.78,79
The importance of GAD antibody titers
in the diagnosis of SPS-SD and distinction
from DM-1
The importance of high GAD titers in connection
with true neurological syndromes, compared with
atypical or non-specific entities and DM-1, has
been recently re-emphasized, pointing out that
anti-GAD antibody titers do matter for diagnosis,
even though their pathogenicity is still unclear.
Patients with the described typical neurological
diseases within the GAD-SDs normally have very
high anti-GAD antibody titers compared with
moderate–low titers in atypical syndromes and
very low titers in DM-1.74 Several assays are being
used to detect anti-GAD antibodies, generating
at times confusion in clinical practice, including
quantitative radio-immunoassays (RIAs) and
ELISAs.27,61,80 These assays, initially developed
journals.sagepub.com/home/tan
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to detect the low titers of GAD antibodies in
DM-1 patients, require adaptations with serial
serum dilutions to ensure the accurate detection
of high titers characteristic of SPS-SD patients.
Other qualitative assays such as tissue immunohistochemistry, cell- based assays or line blots are
mostly useful to detect structural epitopes of
GAD65 antibodies.

be detected in patients receiving IVIg.84 Most
importantly, there is no association between
GAD-Ab titer and disease severity or response to
therapy without significant titer reduction after
immunotherapies with either IVIg or rituximab
based on two controlled studies we have
performed.85,86

Depending on the laboratory and the method
used, reference values may be expressed in different units. A major US clinical laboratory uses RIA
and defines high titers as > or = 20 nmol/L.81,82
According to their experience, these titers are
found in classic SPS (93% positive) and in related
autoimmune neurologic disorders, while values in
patients who have DM-1 without a polyendocrine
or autoimmune neurologic syndrome usually have
titers < or = 20 nmol/L. Other US and European
laboratories use ELISAs, where the cutoff for positivity is >5 IU/mL. According to various clinical
studies in SPS patients, titers are considered high
when they are above 10,000 IU/mL.74 The same
applies to our own laboratory where we use ELISA.
Titers within the range of 5–2000 IU/mL are seen
in DM-1; only titers >10,000 IU/mL are associated with a neurologic disorder. In a recent study,
the significance of serum anti-GAD65 antibody
titers in connection with true neurological disease
was re-confirmed by setting a cutoff value of
10,000 IU/mL in ELISA based on their specificity
in concurrent testing by immunohistochemistry
and cell-based assay. High (>10,000 IU/mL) titers
conferred specificity for an autoimmune neurological disease in 94% of the patients, including SPS,
cerebellar ataxia, chronic epilepsy, limbic encephalitis, or overlapping conditions; in contrast, lower
concentration antibodies were seen in a broader
spectrum of heterogeneous disorders.83 The high
titers were also associated with measurable antiGAD antibodies in the CSF.

Intrathecal synthesis of GAD antibodies
There is strong evidence that in SPS, as well as in
patients with other GAD-SDs, there is intrathecal
synthesis of GAD antibodies. In a pivotal study,
using the Link’s formula, the ratio of GAD antibody concentration in the CSF to that in the
serum was divided by the ratio of albumin concentration in the CSF to that in the serum; on this
basis, values >1 are indicative of robust intrathecal synthesis.57 In clinical practice, when the
serum GAD antibody titers are above 10,000 IU/
mL, GAD antibodies are also detected in the
CSF78 and, in these circumstances, a diagnostic
lumbar puncture may not be necessary, especially
in SPS patients where the stiffness in the lumbar
paraspinals requires a radiology-guided puncture.

Collectively, the practicing neurologists need to
be aware that anti-GAD antibody titers do matter: if high (>10,000 IU/mL), they are diagnostic
for a true GAD-SD, necessitating immunotherapy; lower (<10,000 IU/mL) titers are associated
with atypical or non-specific neurological disorders requiring further investigation, whereas very
low titers (<2000 IU) are typically seen in DM-1
or are of unclear significance.74 Importantly,
GAD-Abs can also be detected within the various
IVIg preparations and anti-GAD antibodies can

journals.sagepub.com/home/tan

The demonstration, however, of intrathecal GAD
antibody synthesis comprises the strongest evidence linking a neurological syndrome to autoimmunity, as suggested.87 In clinical practice, testing
the CSF for GAD antibodies is helpful in patients
with serum titers below 10,000 IU/mL and in
patients with seronegative GAD-spectrum disorder, especially those with encephalitis, and in
patients with a seemingly functional disorder
resembling SPS symptomatology.
GAD epitopes and their potential
significance
GAD exists in two isoforms, GAD65 and GAD67,
each encoded by a different gene, GAD1 and
GAD2, located in chromosomes 2q31.1 and
10p12, respectively.88 GAD65 represents the
membrane form of the enzyme. It is found in synaptic vesicles in the nerve endings and it is mostly
utilized under circumstances where there is an
urgent need of GABA synthesis and release.89,90
GAD67 represents the soluble form, it is abundant
in the cytoplasm and it is implicated in functions
such as synaptogenesis, but not neurotransmission. The two isoforms are divided according to
their linear sequence into three functional domains:

7
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Table 1. Diagnostic work-up.
Clinical evaluation

Electrophysiology

Immunological studies

Neuropsychiatric
examination

•
•

Continuous cocontraction of agonist
and antagonist muscles
with inability to relax

Sera and CSF (when applied) are
tested by ELISA and CBAs for relevant
autoantibodies:
• Anti-GAD
• Anti-GlyR
• Anti-GABAA receptor
• Anti-amphiphysin
• Anti-gephyrin
GAD seronegative patients need to be
examined carefully as they may have a
functional disorder

Structured interviews,
whenever clinically
required, for the Diagnostic
and Statistical Manual for
Mental Disorders (DSM-IV)
Axis I (SCID-I/P) to explore
the origin of anxiety and
phobic symptoms

•

 xial rigidity
A
Episodic spasms often
triggered by unexpected
external stimuli or
emotional upset
No other neurological
diseases that could
account for stiffness

CBA, Cell-based Assay; CSF, cerebrospinal fluid; ELISA, enzyme linked immunosorbent assay; GABAA, gamma-aminobutyric acid A; GAD, glutamic
acid decarboxylase; GlyR, glycine-a1 receptor.

an amino(N)-terminal domain, amino acids-aa
1-188 (1-197); a middle PLP-binding domain,
where the catalytic center of the enzyme resides, aa
189-464 (198-473), and a carboxy (C)-terminal
domain, aa465-585 (474-594).91 The isoforms
show an overall similarity within the middle and
C-terminal domains, having 74% identity, while
the N-terminals have 25%.4 More specifically,
patients with SPS and cerebellar ataxia show
strong immunoreactivity to b78 epitopes, whereas
those with DM-1 recognize more commonly the
b96.11 epitopes.87,92,93 Antibodies against b78
inhibit the enzymatic activity of GAD and provoke
depression in the inhibitory synapsis in rat cerebellar slices, whereas these events are not observed
with antibodies against the b96.11 epitope.35
Patients with DM-1 harbor antibodies directed
against conformational epitopes exclusively located
in the PLP- and C-terminals domains.94,95 In contrast, patients with SPS predominantly recognize
linear epitopes in all three domains96,97 and in the
first 100aa that constitute the regulatory sequence
in the N-terminal domain of GAD65 and does not
react with DM-1 sera.92,98–101 The GAD-Abs
therefore in SPS exhibit a different epitope pattern
of antibody reactivity with distinct biological
effects, compared with DM-1.
Whether different epitope patterns exist among
GAD-related syndromes is unclear. In one study,
GAD-Abs from patients with limbic encephalitis
were more likely to recognize epitopes in the
N-terminal domain, compared with those with
SPS, cerebellar ataxia or epilepsy, with the latter
showing more reactivity to the C-terminal domain
of the enzyme.35,102 In our study, however, of 27
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patients with diverse GAD-related syndromes, no
differences in epitope specificities were found
except in three patients with epilepsy.103
Accordingly, the current data cannot explain the
diverse clinical presentation based on different
epitope binding patterns.
Diagnostic work-up and concerns in
diagnosing GAD-negative SPS
The diagnostic work-up for SPS includes the clinical criteria mentioned earlier in conjunction with
electrophysiological data, and relevant autoantibody seropositivity mainly highlighted by antiGAD with cutoff titers >10.000 IU/mL by
ELISA, as mentioned earlier (Table 1).15,104 The
main difficulty remains the seronegative SPS that
represents close to 20% of patients with seemingly clinical SPS. Considering that functional
components can co-exist in some patients with
high-GAD titers, the main concern in practice is
to ensure that patients with seronegative SPS do
not have a functional disorder or another neurological disease mimicking SPS. Adherence to
strict clinical criteria, neurophysiologic testing
and neuropsychiatric assessment, if needed, are
essential. Although an empirical trial with diazepam is often used, it does not ensure diagnostic
accuracy because it cannot differentiate an
organic from a functional disorder.
Pathogenesis of GAD-SD and biologic basis
of autoimmune hyperexcitability
The pathogenesis of GAD-associated syndromes
is still uncertain. Despite the key role of
journals.sagepub.com/home/tan
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autoantibodies in defining a rather heterogeneous
group of overlapping disorders, it is not yet clear
whether GAD antibodies are pathogenic or markers of aberrantly activated innate and acquired
immunity.
Rats treated intracerebroventricularly with SPSIgG showed a stiffness-like behavior, a decline of
motor function as measured by time on the
Rotarod test and a decrease in forelimb grip
strength as compared with control IgG-infused
rats. Additional studies of passive transfer of
GAD-Abs from patients into rats or mice have
shown continuous motor activity with repetitive
muscle discharges and abnormally enhanced
reflexes with increased excitability of anterior
horn cells.38,39,105 Whether these effects are related
to anti-GAD or other antibodies directed at different synaptic antigens is unclear. On the other
hand, diffusion of IgG and quantification of
enhanced green fluorescent protein-labeled neurons after SPS IgG injection into mice did not
generate any symptoms.106 Furthermore, stereotactic injection of GAD-Abs into the hippocampus of rats in vivo did not alter spontaneous and
evoked GABAergic synaptic transmission.107,108
In contrast to anti-GAD antibodies, animals
treated intraperitoneally109 or intrathecally110 with
IgG anti-amphiphysin Abs have exhibited stiffness-like behavior.
Equally controversial are the data from experiments conducted in cultured neurons.
Hippocampal cultured neurons treated with sera
from epileptic GAD-positive patients showed an
increase of post-synaptic inhibitory potentials
compared with negative controls.111 Further,
when rat cerebellar slices were exposed to serum
or CSF from patients with SPS or cerebellar
ataxia, a decrease of post-synaptic inhibitory
currents of Purkinje cells was observed, compared with GAD-negative sera form ataxic
patients.72,112,113 Some studies have also shown
epitope-dependent pathogenic actions of GADAbs in histological brain sections and in vivo
preparations,35,106,114 whereas others showed
lack of internalization into hippocampal cultured
rat neurons3 (Table 2). It remains, however,
unclear how GAD-Abs can cause the GABAergic
dysfunction in SPS if not internalizing into neurons. The possibility that antigens during synaptic transmission transiently expose extracellular
epitopes, recognized by the immune system,
remains hypothetical.
journals.sagepub.com/home/tan

Circulating GAD-reactive B cells that can differentiate into antibody producing cells have been
also detected in the peripheral blood and bone
marrow of patients with GAD-Ab associated neurological syndromes. Interestingly, the presence
of GAD was not required for induction of GADantibody producing cells and GAD-Ab production by stimulated peripheral blood cells did not
correlate with GAD-Ab serum levels, suggesting
an additional source of GAD-Abs. This study
implied that targeting both memory B cells (i.e.
with rituximab) and plasma cells (i.e. with bortezomib) might be a potential treatment option.115
Anti-GAD antibodies are typically found in the
peripheral blood and in lower levels in the CSF.15
GAD-Abs in CSF on occasion can be detected as
monoclonal bands, suggesting that only a fraction
of the whole anti-GAD response occurs in the
CNS and that the intrathecal production of
GAD-Abs could facilitate their access to relevant
neuronal autoantigens. Interestingly, the intrathecal monoclonal IgGs are reactive to GAD65.3,4
The role of B cells remains, however, unclear.
The statistically negative controlled study with
rituximab (see below) cannot be interpreted to
suggest that B cell suppression and antibody production may not be critical factors, because the
study had an impressive effect in some patients
but it was statistically negative due to a strong
placebo effect. The same may also apply to the
lack of correlation of antibodies titers to disease
severity. Interestingly, it has been observed that
mice possessing a monoclonal GAD65 specific
CD4+ T cell population develop a lethal encephalomyelitis-like disease in the absence of any other
T cells or B cells.116
Therapeutic approaches
SPS patients experience severe anxiety and
depression due to phobias of sustaining falls or
inability in completing even simple physical tasks.
Patients with significant symptoms that do not
improve concurrently with the physical symptomatology need clinical and psychological support
both at home and at work. Their phobias often
lead to depression, or at times addiction to drugs
such as benzodiazepines or narcotics, highlighting
the need for multifactorial care.
For SPS and GAD-SD, two strategies of treatment
are implemented: symptomatic (anti-spasmodic) or
immunologic117 interventions either independently
9
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Table 2. Experimental animal models of glutamic acid decarboxylase antibody-spectrum disorder.
Experimental approach

Sample

Clinical
manifestation

Result

Reference

(a) Stereotactical injection
into rats’ hippocampi

CSF

Focal epilepsy due
to LE

NO changes on GABAergic
transmission

Hackert et al.107

(b) Intraperitoneal injection
into transgenic mice

IgG

PERM and SPS

NO differences in behavioral
tests
NO loss of GAD-EGFP neurons

Chang et al.106

(c) Epitope specificity:
monoclonal GAD Ab in
cerebellar slices and mice

Sera

CA, SPS, LE, T1D

b78 inhibits GAD enzyme activity

Manto et al.35

(d) Whole-cell patch-clamp
technique on cerebellar
slices

IgG from CSF

CA

Effects presynaptically with
suppression of GABAergic
transmission

Mitoma et al.,113
Takenoshita
et al.,72 Ishida
et al.112

(e) Whole-cell patch-clamp
technique on hippocampal
slices

Sera

Epilepsy, T1D

Increase of frequency of IPSPs

Vianello et al.111

(f) GAD-Abs in rat cerebellar
slices

Sera, CSF

SPS, T1D,
autoimmune PS

SPS: reduction of GABA
production
T1D/PS: NO differences in
enzyme’s activity

Dinkel et al.15

(g) Intracerebellar injection
in rats

IgG from sera

SPS, CA,
paraneoplastic CA
(GAD–), T1D

GAD+: altered cerebellar activity,
impaired learning, muscle
discharges, abnormal reflexes
GAD−: NO effect

Manto et al.38

(h) Passive transfer of Abs
in mice

GAD-Abs

–

Loss of GAD-EGFP neurons
NO behavioral changes

Chang et al.107

(i) Intraventricular (i.c.v.) and
intrathecal (i.th) injection

IgG

SPS

i.c.v.: stiffness-like behavior,
impaired walking ability,
sensorimotor dysfunction,
normal anxiety test
i.th: NO motor symptoms;
normal spinal transmission

Hansen et al.105

CA, cerebellar ataxia; CSF, cerebrospinal fluid; EGFP, enhanced green fluorescent protein; GABA, gamma-aminobutyric acid; GAD, glutamic acid
decarboxylase; IPSP, Inhibitory Postsynaptic Potentials; LE, Limbic encephalitis; PERM, progressive encephalomyelitis with rigidity and myoclonus;
PS, polyendocrine syndrome; SPS, stiff person syndrome; T1D, DM-1.

or in combination, depending on symptom severity
(Table 3). Symptomatic relief is often achieved
with agents that enhance GABAergic transmission,
such as benzodiazepines, which diminish spasms
and stiffness, especially those triggered by emotional factors. The first therapeutic option is diazepam, a GABAA agonist. This drug can help most
patients, although the high doses sometimes
required cannot be tolerated and may lead to addiction. Other similar compounds include clonazepam, alprazolam, lorazepam and temazepam. The
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second category of drugs used as anti-spasticity
agents are GABAB agonists. Because of better tolerance and no addiction potential, we have now
started using these agents as first line therapy in lieu
of benzodiazepines. The most effective among
them is baclofen, to the point of now using it as first
in order. Sometimes high doses (up to 60 mg) are
required to induce meaningful improvement,
resulting in some cognitive issues. Antiepileptic
drugs that enhance the brain’s GABAergic transmission also improve symptomatology, either alone
journals.sagepub.com/home/tan
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Table 3. Therapies of stiff person syndrome.
Symptomatic

Immunologic

Drug category

Agents

Effect

Immunomodulating

Effect

GABAA agonists

Diazepam
Chlonazepam
Alprazepam
Lorazepam
Temazepam

Enhance GABAergic
transmission
Can help most patients
High doses: not tolerated

IVIg

The only proven
immunomodulatory therapy:
beneficial in SPS

GABAB agonists

Baclofen

Antispasticity drug
High doses my cause
cognitive effects

Plasmapheresis

Not routinely used:
Inconsistent and transient
benefits

α2 adrenergic
receptor

Tizanidine

Muscle relaxant

Corticosteroids

Mostly ineffective

Ca+2 inhibitor

Dantrolene

Muscle relaxant

Immunosuppressants

Anti-epileptic
drugs

Gabapentin
Vigabartin
Tiagabine
Leveritacetam

Inhibition of GABA
transmission

Azathioprine
Methotrexate
Cyclophosphamide
Cellcept
Rituximab
HSMT

Mostly ineffective
Rituximab, although
statistically insignificant
against placebo, may have
impressive benefits in some
patients

GABA, gamma-aminobutyric acid; HSMT, Hematopoietic Stem Cell Transplantation; IVIg, intravenous immunoglobulin; SPS, stiff person syndrome.

or in conjunction with baclofen and benzodiazepines. In our experience, the most helpful agents
in this family are gabapentin and vigabatrin, which
act by inhibiting GABA-transaminase. Others
include tiagabine, an inhibitor of GABA re-uptake,
and levetiracetam, which facilitates inhibition of
GABAergic transmission. Tizanidine, a centrally
acting α2 adrenergic receptor, and dantrolene, a
muscle relaxant, can also help.
If the above agents do not offer a satisfactory benefit, we proceed to immunotherapy. The most
widely used agent in this category is intravenous
immunoglobulin (IVIg) after its proven efficacy.
In a randomized, double-blinded, placebo-controlled crossover trial we conducted in GADpositive SPS patients, IVIg resulted in significant
improvements in objective stiffness parameters
and activities of daily living.61 The duration of
efficacy after each monthly IVIg infusion ranges
from 4 to 12 weeks in most patients. IVIg remains
the only immunomodulatory therapy with proven
benefit in SPS. Subcutaneous immunoglobulin
may be also an option in patients with poor
venous access, or when there is a demonstrable
early wearing-off effect, ensuring a more sustained benefit. Plasmapheresis has been of limited
journals.sagepub.com/home/tan

and transient benefit and we do not routinely use
it in spite of some anecdotal case reports.117
Corticosteroids are surprisingly ineffective in our
experience with a large number of patients,
although one anecdotal report had shown limited
benefit.118 Furthermore, triggering or exacerbating diabetes is a serious consideration that further
limits its use. Of paramount importance is the
control of diabetes, which requires insulin most
times and, if uncontrolled, seems to worsen the
neurologic symptomatology.
Immunosuppressive agents such as azathioprine,
methotrexate, cyclophosphamide and mycophenolate mofetil are equally disappointing, in spite
of rare anecdotal reports.119,120 The most useful
drug in this category is rituximab. A randomized
controlled trial86 we conducted in patients with
SPS demonstrated lack of efficacy of rituximab
compared with placebo owing to a strong placebo
effect. In this series, however, seven patients
improved and four of them with severe disease
demonstrated meaningful to impressive improvements. On this basis, we believe rituximab is a
useful drug for a subset of patients who have
failed therapies with GABA-enhancing drugs and
IVIg. It should be stressed that anti-GAD
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antibody titers may drop but not to a statistically
significant level and the titers do not correlate or
predict improvement.
Some SPS patients who failed conventional
immunosuppressive therapy have experienced
benefit after autologous hematopoietic stem cell
transplantation (auto-HSCT). In one small study,
three patients with SPS and one with PERM were
initially treated with cyclophosphamide (Cy) 2 g/
m2 + Granulocyte-colony stimulating factors
(G-CSF) and then conditioned with Cy 200 mg/
kg + Anti-thymocyte Globulin (ATG) followed by
auto-HSCT. All patients tolerated the procedure
well and showed improved physical performance.
One patient’s walking distance improved from
300 meters to 5 miles and one other’s ambulation
improved from being confined to a wheelchair to
being able to walk with a frame. Two patients
became seronegative for anti-GAD antibodies and
normalized their neurophysiological abnormalities. Additional studies have also shown some
benefit. Although auto-HSCT was thought promising, a large study aiming at 40 patients was terminated early after recruiting 23 patients because
of lack of efficacy or transient benefits, taking into
account potential serious complications.121,122
One of the many limitations of this study, as
pointed out,123 was the enrollment of patients with
advanced disease. A new Hematopoietic Stem
Cell Transplantation (HSMT) trial in SPS
patients unresponsive to the therapies mentioned
above might be, however, considered for patients
with still early disease, in a controlled trial design
taking into account a strong placebo effect, and
the use of objective validated scales.123
Therapy for the other, non-SPS, GAD-SDs
Therapeutic agents in autoimmune epilepsy, nystagmus and cerebellar disease are the same in the
other GAD-SDs as those discussed in SPS, except if
their manifestation is acute or subacute, as seen in
autoimmune encephalitis. In these circumstances,
we start with intravenous steroids 1000 mg daily for
5 days, followed by IVIg and rituximab, as needed.
Anti-epileptics are added in patients with epilepsy,
although GAD-associated epilepsy is reported
refractory to the above immunomodulatory therapies, often requiring more aggressive immunosuppressive approaches, with mycophenolate motefil or
rituximab.59 Interestingly, exogenous testosterone
replacement therapy has been shown to reduce seizure frequency and intensity.124 In some cases,
12

epilepsy surgery should be considered, although few
beneficial surgical outcomes in GAD-associated
epilepsy patients have been reported.59 Patients
with longer-standing disease and those with cerebellar ataxia, dysarthria and dysphagia have overall less
impressive response to applied therapies.
Conclusion
The review highlights that high-titer anti-GAD
antibodies are associated with an array of distinct
neurological syndromes including SPS, cerebellar
ataxia, epilepsy, limbic encephalitis, abnormal
eye movements. Although high anti-GAD antibodies in serum or their presence in CSF are
important for diagnosis, the titers do not correlate
with disease severity and do not generally predict
response to immunotherapy. Despite considerable efforts, using both in vitro and in vivo preparations, the pathophysiological role of anti-GAD
antibodies has not yet been clarified, suggesting
that other autoantibodies affecting inhibitory
neurotransmission might be of importance,
because autoimmunity targeting inhibitory synaptic antigens point to a unifying theme of hyperexcitability as the underlying pathomechanism.
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